Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.
Stamford Hospital (www.stamfordhospital.org) is a not-for-profit provider of comprehensive healthcare services in Connecticut. The mission of Stamford Hospital is to provide, together with its physicians, a broad range of high quality health and wellness services focused on the needs of the communities it serves. Stamford Hospital is a member of the Planetree Alliance, a group of hospitals nationwide focused on patient-centered care. Stamford Hospital is affiliated with the New York Presbyterian Health System and is a major teaching affiliate of the Columbia University College of Physicians and Surgeons.